Here are five things to know:
1. The financing round is being led by Avalon Ventures.
2. Ankasa is focusing on the development of the stem cell growth factor WNT3A, which is found in humans and helps maintain bone growth and repair.
3. The company intends to initially develop a proprietary localized therapy involving WNT3A for spinal fusion surgery patients.
4. If approved for commercial use, the stem cell growth factor could serve as an alternative to the protein BMP-2.
5. The company also intends to study the use of WNT3A in additional bone and tissue repair applications.
More articles on devices:
Bioness receives Gold Seal of Approval from the Joint Commission
Stryker shares increase by 1.26% this week — 5 facts
K2M co-founder Dr. John Kostuik sells 46k shares: 6 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
